Alecensaro (alectinib)

pCPA File Number: 22922

Negotiation Status:

Concluded with an LOI

Indication(s):

Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0350-000

pCPA Engagement Letter Issued:

2025-01-14

Negotiation Process Concluded:

2025-04-28